SCHEMBL4802687

SCHEMBL4802687

COc1ccc2c(C(O)CO)coc2c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIN1 Q13526 1/20 0.51
XDH P47989 1/20 0.48
MAPT P10636 6/20 0.47
ALDH1A1 P00352 5/20 0.47
KDM4E B2RXH2 4/20 0.47
RAB9A P51151 4/20 0.47
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
NPC1 O15118 3/20 0.47
TP53 P04637 2/20 0.47
CYP3A4 P08684 2/20 0.47
HPGD P15428 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
CYP2D6 P10635 2/20 0.43
CYP2C19 P33261 2/20 0.43
CYP1A2 P05177 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
CYP11B1 P15538 1/20 0.42
CYP11B2 P19099 1/20 0.42
MAOA P21397 3/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23135513 0.80 PIN1 (0.54) PIN1XDHMAPTALDH1A1KDM4E
SCHEMBL25447343 0.78 PIN1 (0.49) PIN1XDHMAPTALDH1A1KDM4E
SCHEMBL205244 0.75 POLB (0.53) PIN1XDHMAPTALDH1A1KDM4E
SCHEMBL4143937 0.75 AKR1C3 (0.52) PIN1XDHMAPTALDH1A1KDM4E
SCHEMBL4131741 0.73 PIN1 (0.54) PIN1XDHMAPTALDH1A1KDM4E
SCHEMBL5447303 0.72 ALDH1A1 (0.50) PIN1XDHMAPTALDH1A1KDM4E
SCHEMBL31299896 0.71 PIN1 (0.58) PIN1XDHMAPTALDH1A1KDM4E
SCHEMBL10171847 0.71 PIN1 (0.58) PIN1XDHMAPTALDH1A1KDM4E
SCHEMBL11618513 0.71 CYP11B1 (0.64) PIN1XDHMAPTALDH1A1KDM4E
SCHEMBL23188008 0.70 CYP11B1 (0.57) PIN1MAPTALDH1A1KDM4ERAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101133056-B Antitumor compounds NAT HEALTH RESEARCH INSTITUTES 2010-12-01 CN disclosed
US-7456289-B2 Anti-tumor compounds NATIONAL HEALTH RESEARCH INSTITUTES (TW) 2008-11-25 US disclosed
CN-101133056-A Antitumor compounds NAT HEALTH RESEARCH INSTITUTES (CN) 2008-02-27 CN disclosed
EP-1838711-A2 ANTI-TUMOR COMPOUNDS National Health Research Institutes (TW) 2007-10-03 EP disclosed
WO-2006074041-A2 ANTI-TUMOR COMPOUNDS NATIONAL HEALTH RESEARCH INSTITUTES (TW) 2006-07-13 WO disclosed
US-20060148801-A1 Anti-tumor compounds NATIONAL HEALTH RESEARCH INSTITUTES (TW) 2006-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060148801-A1 Anti-tumor compounds TUBB1, TUBB3, TUBB PIN1 1909/4885XDH 639/4885MAPT 47/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.